Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2003004498 - PYRAZINES BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) ET PYRAZINES TETRAHYDROTRIOAZOLO (4, 3-A) UTILISEES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE DANS LE TRAITEMENT OU LA PREVENTION DU DIABETE

Numéro de publication WO/2003/004498
Date de publication 16.01.2003
N° de la demande internationale PCT/US2002/021349
Date du dépôt international 05.07.2002
Demande présentée en vertu du Chapitre 2 06.01.2003
CIB
C07D 487/04 2006.01
CCHIMIE; MÉTALLURGIE
07CHIMIE ORGANIQUE
DCOMPOSÉS HÉTÉROCYCLIQUES
487Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes C07D451/-C07D477/187
02dans lesquels le système condensé contient deux hétérocycles
04Systèmes condensés en ortho
CPC
A61K 31/498
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
498Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/4985
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 38/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
22Hormones
28Insulins
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 1/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Déposants
  • MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue Rahway, NJ 07065-0907, US (AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NE, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SN, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW)
  • EDMONDSON, Scott, D. [US/US]; US (UsOnly)
  • FISHER, Michael, H. [US/US]; US (UsOnly)
  • KIM, Dooseop [KR/US]; US (UsOnly)
  • MACCOSS, Malcolm [GB/US]; US (UsOnly)
  • PARMEE, Emma, R. [GB/US]; US (UsOnly)
  • WEBER, Ann, E. [US/US]; US (UsOnly)
  • XU, Jinyou [CN/US]; US (UsOnly)
Inventeurs
  • EDMONDSON, Scott, D.; US
  • FISHER, Michael, H.; US
  • KIM, Dooseop; US
  • MACCOSS, Malcolm; US
  • PARMEE, Emma, R.; US
  • WEBER, Ann, E.; US
  • XU, Jinyou; US
Représentant commun
  • MERCK & CO., INC.; 126 East Lincoln Avenue Rahway, NJ 07065-0907, US
Données relatives à la priorité
60/303,47406.07.2001US
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) PYRAZINES AND TETRAHYDROTRIOAZOLO (4, 3-A) PYRAZINES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
(FR) PYRAZINES BETA-AMINO TETRAHYDROIMIDAZO (1, 2-A) ET PYRAZINES TETRAHYDROTRIOAZOLO (4, 3-A) UTILISEES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE DANS LE TRAITEMENT OU LA PREVENTION DU DIABETE
Abrégé
(EN)
The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.
(FR)
L'invention a trait à des composés inhibiteurs de la dipeptidyl peptidase IV ('inhibiteurs DP-IV ') qui sont utiles dans le traitement ou dans la prévention des maladies dans lesquelles est impliquée dipeptidyl peptidase IV, telles que le diabète et notamment le diabète de type 2. L'invention a également trait à des compositions pharmaceutiques comprenant ces composés et à l'utilisation de ces composés et compositions dans la prévention ou dans le traitement de ces maladies dans lesquelles dipeptidyl peptidase IV est impliquée.
Également publié en tant que
BG108493
BZ351.03
CRCR2004-007235
CZPV2004-16
GE5445
GE8042
GE8042/1
HRP20031098A
IS7062
IS8617
NO20040021
NZ529833
PH1-2004-500013
PH12004500013
RSP-1006/03
SK16352003
SK200301635
YUP-1006/03
ZA200309294
Dernières données bibliographiques dont dispose le Bureau international